Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 References  





2 See also  














Technetium (99mTc) sulesomab






Italiano
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 

(Redirected from Sulesomab)

Technetium (99mTc) sulesomab
Monoclonal antibody
TypeFab' fragment
SourceMouse
TargetNCA-90 (granulocyte cell antigen)
Clinical data
ATC code
Legal status
Legal status
  • AU: Approved
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]

It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis[4][5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.[10]

References

[edit]
  1. ^ "WHO Drug Information" (PDF). Archived from the original (PDF) on 2012-02-19. Retrieved 2009-10-25.
  • ^ Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ (2008). "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice. 17 (6): 447–52. doi:10.1159/000151565. PMID 18836272.
  • ^ Skehan SJ, White JF, Evans JW, Parry-Jones DR, Solanki CK, Ballinger JR, et al. (January 2003). "Mechanism of accumulation of 99mTc-sulesomab in inflammation". Journal of Nuclear Medicine. 44 (1): 11–8. PMID 12515870. Archived from the original on 2019-12-10. Retrieved 2019-12-10.
  • ^ EMEA: Summary of product characteristics (LeukoScan) Archived 2006-11-22 at the Wayback Machine
  • ^ Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H (December 2016). "Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 60 (4): 413–23. PMID 25325395.
  • ^ Vicente AG, Almoguera M, Alonso JC, Heffernan AJ, Gomez A, Contreras PI, Martin-Comin J (December 2004). "Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2)". Clinical Nuclear Medicine. 29 (12): 781–5. doi:10.1097/00003072-200412000-00001. PMID 15545877. S2CID 46580717.
  • ^ Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ (2008). "Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections". Medical Principles and Practice. 17 (6): 447–52. doi:10.1159/000151565. PMID 18836272.
  • ^ Galletti F, Cammaroto G, Galletti B, Quartuccio N, Di Mauro F, Baldari S (June 2015). "Technetium-99m (99mTc)-labelled sulesomab in the management of malignant external otitis: is there any role?". European Archives of Oto-Rhino-Laryngology. 272 (6): 1377–82. doi:10.1007/s00405-014-2938-1. PMID 24534898. S2CID 25194736.
  • ^ Iyengar KP, Vinjamuri S (June 2005). "Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections". Nuclear Medicine Communications. 26 (6): 489–96. doi:10.1097/00006231-200506000-00003. PMID 15891591. S2CID 41915486.
  • ^ "Products". Immunomedics. Archived from the original on 2019-12-10. Retrieved 2019-12-10.
  • See also

    [edit]


  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Technetium_(99mTc)_sulesomab&oldid=1135492311"

    Categories: 
    Radiopharmaceuticals
    Technetium-99m
    Antibody-drug conjugates
    Technetium compounds
    Monoclonal antibody stubs
    Hidden categories: 
    Webarchive template wayback links
    Articles with short description
    Short description matches Wikidata
    Drugs with non-standard legal status
    Chemicals that do not have a ChemSpider ID assigned
    Infobox drug articles with non-default infobox title
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Articles without InChI source
    Drugs with no legal status
    Drugboxes which contain changes to verified fields
    Drugs that are a monoclonal antibody
    All stub articles
     



    This page was last edited on 25 January 2023, at 00:18 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki